Trial · NCT02388165
Trial comparisons13
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
1 to 13 of 13
Download this page as JSON| Comparison | Source |
|---|---|
Staphylococcus Aureus 4-antigen (SA4Ag) vs Placebo: Number of Participants With Newly Diagnosed Chronic Medical Disorders From First Postoperative Evaluation on Day 42 Until Last Postoperative Evaluation on Day 180 | Trial comparisons |
Staphylococcus Aureus 4-antigen (SA4Ag) vs Placebo: Number of Participants With Postoperative Staphylococcus (S.) Aureus Bloodstream Infection (BSI) And/or Surgical-site Infection (SSI-Including Deep Incisional or Organ/Space) Occurred Within 90 Days After Spinal Surgery | Trial comparisons |
Staphylococcus Aureus 4-antigen (SA4Ag) vs Placebo: Number of Participants With Any Postoperative S. Aureus Surgical-site Infection (SSI-Superficial, Deep Incisional or Organ/Space) Occurred Within 180 Days After Surgery | Trial comparisons |
| Staphylococcus Aureus 4-antigen (SA4Ag) vs Placebo: Number of Participants With Adverse Events (AEs) From The Day of Surgery (Day 1) Until First Postoperative Evaluation on Day 42 | Trial comparisons |
| Staphylococcus Aureus 4-antigen (SA4Ag) vs Placebo: Number of Participants With Adverse Events (AEs) From Vaccination Until First Postoperative Evaluation on Day 42 | Trial comparisons |
Staphylococcus Aureus 4-antigen (SA4Ag) vs Placebo: Number of Participants With Any Postoperative S. Aureus Surgical-site Infection (SSI-Superficial, Deep Incisional or Organ/Space) Occurred Within 90 Days After Surgery | Trial comparisons |
| Staphylococcus Aureus 4-antigen (SA4Ag) vs Placebo: Number of Participants With Serious Adverse Events (SAEs) From Vaccination Until Day of Surgery (Day 1) | Trial comparisons |
| Staphylococcus Aureus 4-antigen (SA4Ag) vs Placebo: Number of Participants With Serious Adverse Events (SAEs) From The Day of Surgery (Day 1) Until Last Postoperative Evaluation on Day 180 | Trial comparisons |
| Staphylococcus Aureus 4-antigen (SA4Ag) vs Placebo: Number of Participants With Serious Adverse Events (SAEs) From Vaccination Until Last Postoperative Evaluation on Day 180 | Trial comparisons |
Staphylococcus Aureus 4-antigen (SA4Ag) vs Placebo: Number of Participants With Postoperative S. Aureus Blood Stream Infection (BSI) And/or Surgical-site Infection (SSI-Including Deep Incisional or Organ/Space) Occurred Within 180 Days After Surgery | Trial comparisons |
| Staphylococcus Aureus 4-antigen (SA4Ag) vs Placebo: Number of Participants With Adverse Events (AEs) From Vaccination Until The Day of Surgery (Day 1) | Trial comparisons |
| Staphylococcus Aureus 4-antigen (SA4Ag) vs Placebo: deaths from any cause | Trial comparisons |
| Staphylococcus Aureus 4-antigen (SA4Ag) vs Placebo: serious adverse events | Trial comparisons |
trials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02388165/comparisons